http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-576065-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2007-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22420172cfe00f9989035235b6ae81f3 |
| publicationDate | 2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-576065-A |
| titleOfInvention | Method for treating cancer harboring egfr mutations |
| abstract | Provided is the use of an irreversible EGFR inhibitor BIBW 2992 for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring a mutation of the EGFR gene in the tumour, and wherein the cancer shows resistance or acquired resistance to treatment with gefitinib and/or erlotinib. The inhibitor can be combined with other further chemotherapeutic agents. |
| priorityDate | 2006-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 862.